The U.S. Food and Drug Administration (FDA) has given fast track status to stenoparib, an experimental treatment Allarity Therapeutics has been testing for advanced…
Gynecological cancer
GYNECOLOGICAL CANCER
Ovarian cancer patients wanted for Phase 3 trial of virus therapy
A Phase 3 clinical trial testing the experimental cancer-killing virus Olvi-Vec in people with hard-to-treat ovarian cancer is recruiting participants. Top-line results from the ongoing…
GYNECOLOGICAL CANCER
2 of 3 ovarian cancer patients in study respond to SON-1010 combo
Sonnet Biotherapeutics is now testing its immunotherapy SON-1010, in combination with the immune checkpoint inhibitor Tecentriq (atezolizumab), in more patients — and soon, at…
GYNECOLOGICAL CANCER
Intervenn’s noninvasive ovarian cancer test to hit market this fall
A noninvasive diagnostic test to help distinguish ovarian cancer from benign pelvic masses will be available this fall. GlycoKnow Ovarian received a proprietary laboratory…
GYNECOLOGICAL CANCER
Projections show uterine cancer cases, mortality rate, on rise in US
The number of uterine cancer cases and related deaths — the disease’s incidence and mortality rates — in the U.S. are expected to substantially rise…
GYNECOLOGICAL CANCER
Approval sought of relacorilant for platinum-resistant ovarian cancer
Corcept Therapeutics has asked the U.S. Food and Drug Administration (FDA) to approve relacorilant, to be used in combination with the standard chemotherapy agent…
GYNECOLOGICAL CANCER
CAR-T cell therapy for ovarian cancer enters next phase of testing
A Phase 1 clinical trial evaluating escalating doses of Anixa Biosciences’ experimental CAR T-cell therapy for recurrent ovarian cancer has begun dosing participants…
GYNECOLOGICAL CANCER
Trial of BAT8006 for form of ovarian cancer doses 1st patient
The first patient has been dosed in a Phase 3 trial testing the investigational therapy BAT8006 in people with platinum-resistant ovarian cancer, according to the…
GYNECOLOGICAL CANCER
Ovarian cancer immunotherapy found to boost immune response
IMNN-001, Imunon’s experimental immunotherapy for advanced ovarian cancer, boosts the body’s natural immune response by increasing levels of immune signaling proteins that aid in…
GYNECOLOGICAL CANCER
1st patient dosed in trial of Enhertu for HER2 endometrial cancer
A Phase 3 clinical trial of Enhertu, a therapy developed by Daiichi Sankyo and AstraZeneca, has begun dosing its first patient with…
Recent Posts
- I’m taking up walking to combat the fog of ‘chemo brain’
- FDA OKs first-in-human trial of cell therapy for hard-to-treat AML
- First-of-its-kind solid tumor cell therapy prepares to debut in China
- Patients and caregivers can tap into the power of humor, too
- New brain cancer treatment for children awarded FDA orphan status
